MCID: PRP080
MIFTS: 54

Peripheral Artery Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Peripheral Artery Disease

MalaCards integrated aliases for Peripheral Artery Disease:

Name: Peripheral Artery Disease 12 6 15
Peripheral Arterial Diseases 70
Peripheral Arterial Disease 44

Classifications:



External Ids:

Disease Ontology 12 DOID:0050830
MeSH 44 D058729
UMLS 70 C1704436

Summaries for Peripheral Artery Disease

Disease Ontology : 12 An artery disease that is characterized by build up of plaque in the arteries that carry blood to your head, organs, and limbs.

MalaCards based summary : Peripheral Artery Disease, also known as peripheral arterial diseases, is related to intermittent claudication and arteries, anomalies of, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Peripheral Artery Disease is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Simvastatin and Ramipril have been mentioned in the context of this disorder. Affiliated tissues include endothelial, bone marrow and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Peripheral artery disease (PAD) is an abnormal narrowing of arteries other than those that supply the... more...

Related Diseases for Peripheral Artery Disease

Diseases related to Peripheral Artery Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 808)
# Related Disease Score Top Affiliating Genes
1 intermittent claudication 31.7 VWF VEGFA SELP IL6 CRP ACE
2 arteries, anomalies of 31.3 VEGFA VCAM1 TNF NOS3 IL6 ICAM1
3 ischemia 31.2 VEGFA SELP NOS3 ICAM1 HIF1A EDN1
4 atrial fibrillation 31.2 VWF SELP CRP ACE
5 coronary heart disease 1 31.1 PCSK9 CRP APOE APOB ACE
6 peripheral vascular disease 31.1 VWF VEGFA VCAM1 SELP IL6 F3
7 lipid metabolism disorder 31.0 IL6 CRP CCL2 APOE APOB ACE
8 limb ischemia 30.9 VWF VEGFA TNF NOS3 IL6 ICAM1
9 thrombosis 30.9 VWF SELP P2RY12 F3
10 hypercholesterolemia, familial, 1 30.9 PCSK9 NOS3 CRP APOE APOB ACE
11 pulmonary disease, chronic obstructive 30.8 TNF IL6 CRP CCL2 ACE
12 impotence 30.7 NOS3 EDN1 ACE
13 renovascular hypertension 30.7 NOS3 EDN1 ACE
14 pulmonary embolism 30.6 VWF F3 CRP ACE
15 decubitus ulcer 30.6 VEGFA TNF IL6 CRP
16 hypothyroidism 30.6 VWF TNF CST3 CRP APOB ACE
17 chickenpox 30.5 TNF IL6 CRP
18 arteriosclerosis obliterans 30.5 VCAM1 SELP IL6 ICAM1
19 polyneuropathy 30.4 VEGFA TNF IL6 CRP ACE
20 carotid artery disease 30.4 SELP F3 CRP CCL2 APOE APOB
21 compartment syndrome 30.4 TNF IL6 F3 CRP
22 left bundle branch hemiblock 30.4 P2RY12 CRP ACE
23 hyperglycemia 30.4 VCAM1 NOS3 IL6 HIF1A APOB
24 congestive heart failure 30.4 VEGFA TNF NOS3 IL6 EDN1 CRP
25 generalized atherosclerosis 30.4 VWF IL6 CRP APOE APOB ACE
26 diabetic angiopathy 30.4 VWF NOS3 EDN1 CCL2
27 chlamydia 30.4 TNF IL6 CRP CCL2
28 renal artery disease 30.4 NOS3 CST3 ACE
29 temporal arteritis 30.4 TNF IL6 CRP CCL2
30 ulcer of lower limbs 30.3 VEGFA TNF IL6
31 renal hypertension 30.3 NOS3 EDN1 ACE
32 active peptic ulcer disease 30.3 VWF F3 CRP
33 erysipelas 30.3 TNF IL6 CRP
34 thyroiditis 30.3 TNF IL6 CRP
35 aortitis 30.3 TNF IL6 CRP
36 peripheral nervous system disease 30.3 VEGFA TNF IL6 HIF1A CRP CCL2
37 cardiogenic shock 30.3 TNF IL6
38 chronic venous insufficiency 30.3 VEGFA VCAM1 SELP ICAM1 CRP
39 buerger disease 30.3 VEGFA VCAM1 ICAM1 EDN1 CRP
40 cerebrovascular disease 30.3 VWF VCAM1 TNF SELP IL6 ICAM1
41 von willebrand's disease 30.3 VWF SELP F3
42 meningoencephalitis 30.3 TNF IL6 CRP
43 tricuspid valve insufficiency 30.3 F3 EDN1 CRP ACE
44 hypertensive retinopathy 30.2 VWF VEGFA CRP ACE
45 glomerulonephritis 30.2 VCAM1 ICAM1 CCL2 ACE
46 deficiency anemia 30.2 TNF SELP IL6 HIF1A CST3 CRP
47 chronic ulcer of skin 30.2 VEGFA TNF IL6 CRP
48 anthracosis 30.2 TNF IL6 CCL2
49 polycythemia 30.2 VEGFA HIF1A EDN1 ACE
50 mental depression 30.2 TNF IL6 CRP

Graphical network of the top 20 diseases related to Peripheral Artery Disease:



Diseases related to Peripheral Artery Disease

Symptoms & Phenotypes for Peripheral Artery Disease

UMLS symptoms related to Peripheral Artery Disease:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Peripheral Artery Disease:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 ACE APOB APOE CRP CST3 EDN1
2 homeostasis/metabolism MP:0005376 10.43 ACE APOB APOE CRP CST3 EDN1
3 cellular MP:0005384 10.34 APOB APOE CST3 F3 HIF1A ICAM1
4 immune system MP:0005387 10.33 ACE APOB APOE CCL2 CRP F3
5 hematopoietic system MP:0005397 10.31 ACE APOE F3 HIF1A ICAM1 IL6
6 mortality/aging MP:0010768 10.28 ACE APOB APOE CST3 EDN1 F3
7 digestive/alimentary MP:0005381 10.16 APOE EDN1 HIF1A ICAM1 IL6 NOS3
8 liver/biliary system MP:0005370 10.13 ACE APOB APOE HIF1A IL6 NOS3
9 muscle MP:0005369 10.11 APOB APOE CST3 EDN1 F3 HIF1A
10 nervous system MP:0003631 10.1 ACE APOB APOE CST3 EDN1 F3
11 neoplasm MP:0002006 9.92 ACE CST3 F3 HIF1A ICAM1 IL6
12 renal/urinary system MP:0005367 9.76 ACE APOE EDN1 HIF1A IL6 NOS3
13 respiratory system MP:0005388 9.56 APOE F3 HIF1A IL6 NOS3 SELP
14 vision/eye MP:0005391 9.36 ACE APOB APOE F3 HIF1A ICAM1

Drugs & Therapeutics for Peripheral Artery Disease

Drugs for Peripheral Artery Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Ramipril Approved Phase 4 87333-19-5 5362129
3
Ezetimibe Approved Phase 4 163222-33-1 150311
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
6
Thrombin Approved, Investigational Phase 4
7
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
8
Allopurinol Approved Phase 4 315-30-0 2094
9
Dalteparin Approved Phase 4 9005-49-6
10
Defibrotide Approved, Investigational Phase 4 83712-60-1
11
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
12
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
13
Testosterone Approved, Investigational Phase 4 58-22-0 6013
14
Methyltestosterone Approved Phase 4 58-18-4 6010
15
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
16
Testosterone enanthate Approved Phase 4 315-37-7 9416
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Glucagon Approved Phase 4 16941-32-5
20
Evolocumab Approved Phase 4 1256937-27-5
21
Iron Approved Phase 4 7439-89-6 23925 29936
22
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
23
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
24
Liraglutide Approved Phase 4 204656-20-2 44147092
25
Rivaroxaban Approved Phase 4 366789-02-8
26
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
27
Metformin Approved Phase 4 657-24-9 4091 14219
28
tannic acid Approved Phase 4 1401-55-4
29
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
30
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
31
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
32
Zinc Approved, Investigational Phase 4 7440-66-6 32051
33
Insulin glargine Approved Phase 4 160337-95-1
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
35
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
36
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
37
Sarpogrelate Investigational Phase 4 125926-17-2 5160
38 Mitogens Phase 4
39 Androgens Phase 4
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
41 Hypolipidemic Agents Phase 4
42 Phosphodiesterase Inhibitors Phase 4
43 carnitine Phase 4
44 Hemostatics Phase 4
45 Endothelial Growth Factors Phase 4
46 Coagulants Phase 4
47 Chelating Agents Phase 4
48 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
49 Heparin, Low-Molecular-Weight Phase 4
50 Eicosapentaenoic acid ethyl ester Phase 4

Interventional clinical trials:

(show top 50) (show all 1162)
# Name Status NCT ID Phase Drugs
1 Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs Unknown status NCT01424020 Phase 4
2 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
3 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
4 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
5 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
6 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
7 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
8 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
9 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
10 Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis Unknown status NCT02842424 Phase 4 Ramipril
11 In.Pact Flexion, a Physician Initiated Trial Investigating the Performance of the In.Pact Admiral Drug-eluting Balloon for the Treatment of Popliteal Lesions Unknown status NCT02678065 Phase 4
12 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
13 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
14 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
15 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
16 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
17 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
18 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
19 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
20 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
21 Jetstream NAVITUS™ System Endovascular Therapy Post-market Registry (JET) Completed NCT01436435 Phase 4
22 Evaluation of a Strategy for Systematic Screening for Vitamin D Deficiency and Treatment in Case of Deficiency, on the Improvement of the Maximum Walking Distance in Patients With Stage 2 Lower Limb Arterial Disease. Completed NCT03615833 Phase 4 Cholecalciferol
23 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD Completed NCT01952756 Phase 4 Cilostazol;Dummy Placebo
24 The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study Completed NCT00911417 Phase 4
25 ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease Completed NCT00681226 Phase 4 Ramipril or matching placebo
26 Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study Completed NCT01556542 Phase 4
27 Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study Completed NCT02548650 Phase 4 Vorapaxar;Clopidogrel;Aspirin
28 Phase IV Study of Statins for Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease Completed NCT01041729 Phase 4 Atorvastatin;Standard Medical Treatment
29 A Prospective, Randomized, Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease Completed NCT00640770 Phase 4
30 Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
31 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
32 NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions Completed NCT01783600 Phase 4
33 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
34 The Effects of Physical Training, Aspirin, and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease Completed NCT00189618 Phase 4 Aspirin;Clopidogrel
35 BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions Completed NCT02690051 Phase 4
36 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4 Control
37 Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ("The ELIMIT Trial") Completed NCT00687076 Phase 4 Ezetimibe;Niaspan;Statin therapy;Aspirin;Clopidogrel;Placebo Niaspan;Placebo Ezetimibe
38 Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases Completed NCT00955617 Phase 4
39 DURABILITY+ : a Prospective, Multi-center, Controlled Study Measuring the Durability in Lesions of the Superficial Femoral Artery of the Protégé Everflex+ Stent Completed NCT01412463 Phase 4
40 DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions Completed NCT01412450 Phase 4
41 Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases Completed NCT01026389 Phase 4 Dotarem;Gadovist
42 Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb), Unsuitable or Suitable to Surgical Revascularization / Endovascular With Reference to the Change of Pain-free Walking Distance and Other Endpoints Completed NCT01718288 Phase 4 iloprost;Standard Treatment (aspirin.....),
43 Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease Completed NCT00648453 Phase 4 Clopidogrel (Plavix)
44 A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions Completed NCT01273623 Phase 4
45 A Randomized, Dose-controlled, Open-label, Parallel, 2-treatment Group, Single Center, Pilot Study to Evaluate the Effectiveness of Sarpogrelate on Blood Hyperviscosity in the Patients With Peripheral Arterial Disease Completed NCT03509922 Phase 4 Anplag Tab. 100mg bid;Anplag Tab. 100mg tid
46 Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis Completed NCT01083030 Phase 4
47 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
48 Investigation of the Arterial Effects of the Veinoplus(r) Stimlator Device. Completed NCT01592812 Phase 4
49 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Completed NCT02563535 Phase 4
50 Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease. Completed NCT02983214 Phase 4 Clopidogrel;Cilostazol

Search NIH Clinical Center for Peripheral Artery Disease

Cochrane evidence based reviews: peripheral arterial disease

Genetic Tests for Peripheral Artery Disease

Anatomical Context for Peripheral Artery Disease

MalaCards organs/tissues related to Peripheral Artery Disease:

40
Endothelial, Bone Marrow, Kidney, Bone, Skeletal Muscle, Heart, Placenta

Publications for Peripheral Artery Disease

Articles related to Peripheral Artery Disease:

(show top 50) (show all 5772)
# Title Authors PMID Year
1
Variability in utilization of diagnostic imaging tests in patients with symptomatic peripheral artery disease. 61
33581177 2021
2
Current-Induced Vasodilation Specifically Detects, and Correlates With the Time Since, Last Aspirin Intake: An Interventional Study of 830 Patients. 61
33161777 2021
3
Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015. 61
33248925 2021
4
Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study. 61
32803534 2021
5
Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation. 61
33794654 2021
6
Comparison of postoperative outcomes between robotic mitral valve replacement and conventional mitral valve replacement. 61
33566393 2021
7
Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. 61
32252582 2021
8
A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. 61
33161072 2021
9
In-Hospital Outcomes and Trends of Endovascular Intervention vs Surgical Revascularization in Octogenarians With Peripheral Artery Disease. 61
33460607 2021
10
The Society for Vascular Surgery Alternative Payment Model Task Force report on opportunities for value-based reimbursement in care for patients with peripheral artery disease. 61
32931874 2021
11
Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. 61
33065765 2021
12
Nerve growth factor in muscle afferent neurons of peripheral artery disease and autonomic function. 61
33063730 2021
13
Gene Expression Signature in Patients With Symptomatic Peripheral Artery Disease. 61
33657880 2021
14
The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. 61
32891803 2021
15
Association between Physical Activity and Mortality in Patients with Claudication. 61
32991346 2021
16
Feasibility and Safety of the Direct Occluded Vessel Puncture Technique as a New Access Site for Complex Peripheral Artery Occlusive Disease. 61
32565529 2021
17
The Future of Aspirin Therapy in Cardiovascular Disease. 61
33706989 2021
18
Relationship between carotid intraplaque neovascularization and haemoglobin A1c in diabetic patients. 61
33601236 2021
19
Evolution of Major Amputation Risk in Patients Hospitalized in France for Critical Limb Ischemia: The COPART Registry. 61
33267644 2021
20
Impact of Multivascular Disease on Cardiovascular Mortality and Morbidity in Patients Receiving Hemodialysis: Ten-Year Outcomes of the Q-Cohort Study. 61
32684556 2021
21
Do we have a unified consensus on antithrombotic management of PAD? 61
33739074 2021
22
The cardiovascular safety of oral alitretinoin. A population-based cohort study involving 19,513 patients exposed to oral alitretinoin. 61
33735442 2021
23
Acute kidney injury following endovascular intervention for peripheral artery disease. 61
33711140 2021
24
Is multiple sclerosis a risk factor for atherosclerosis? 61
31707002 2021
25
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. 61
33038480 2021
26
Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. 61
33667437 2021
27
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. 61
33704652 2021
28
The Effect of Preoperative Renal Failure on Outcomes Following Infrainguinal Endovascular Interventions for Peripheral Arterial Disease. 61
33386206 2021
29
Effects of dual antiplatelet therapy on graft patency after lower extremity bypass. 61
32777321 2021
30
Microvascular and macrovascular complications in type 2 diabetes in a multi-ethnic population based in Amsterdam. The HELIUS study. 61
33676869 2021
31
Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway and Sweden according to national ongoing registries. 61
33710273 2021
32
Abnormal vascular physiology in the lower extremities as a risk factor for ischemic stroke and mortality. 61
33691353 2021
33
A National Canadian Survey of Antithrombotic Therapy After Urgent and Emergent Limb Revascularization. 61
32585326 2021
34
Elevated HDL-bound miR-181c-5p level is associated with diabetic vascular complications in Australian Aboriginal people. 61
33651121 2021
35
Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus. 61
33808800 2021
36
Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation. 61
33754300 2021
37
Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study. 61
33785415 2021
38
A Severe Necrotizing Inflammatory Reaction of Leg Wounds Following Autologous Peripheral Blood Total Nucleated Cells Treatment in an Old Patient With Rheumatoid Arthritis and No-Option Chronic Limb-Threatening Ischemia: Is Cell Therapy Suitable for All Patients? 61
33719646 2021
39
Patient Reported Outcome Measures for Major Lower Limb Amputation Caused by Peripheral Artery Disease or Diabetes: A Systematic Review. 61
33388237 2021
40
Intermittent Administration of Nitroglycerin Sublingual Powder Compared with Placebo in Outpatients with Peripheral Artery Disease: Results of a Randomised Proof of Concept Study. 61
33358350 2021
41
Prevalence of the Academic Research Consortium high bleeding risk criteria in patients undergoing endovascular therapy for peripheral artery disease in lower extremities. 61
33651134 2021
42
The Monocyte/High Density Lipoprotein Cholesterol Ratio (MHR) as an Indicator of the Need for Amputation in Patients With Peripheral Artery Disease Developing Critical Limb Ischemia. 61
33108889 2021
43
Long-term clinical outcome and mortality risks after paclitaxel-coated balloon angioplasty in patients with peripheral artery disease: An observational clinical study. 61
33532599 2021
44
Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. 61
33409569 2021
45
Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design. 61
33714278 2021
46
Higher long-term mortality after endovascular vs. open-surgical revascularization of peripheral artery disease in Australia and New Zealand? 61
33742201 2021
47
The Safety of Paclitaxel-Coated Devices for Patients with Peripheral Artery Disease. 61
33738616 2021
48
Treatment of Varicose Veins Affects the Incidences of Venous Thromboembolism and Peripheral Artery Disease. 61
33685215 2021
49
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. 61
33504178 2021
50
Partial home confinement during the COVID-19 pandemic, physical function, and physical activity in patients with symptomatic lower extremity peripheral artery disease. 61
33733966 2021

Variations for Peripheral Artery Disease

Expression for Peripheral Artery Disease

Search GEO for disease gene expression data for Peripheral Artery Disease.

Pathways for Peripheral Artery Disease

Pathways related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 VWF VEGFA VCAM1 TNF NOS3 IL6
2
Show member pathways
13.33 VWF VEGFA VCAM1 TNF IL6 ICAM1
3
Show member pathways
13.29 VWF VEGFA SELP P2RY12 NOS3 F3
4
Show member pathways
13.17 VCAM1 TNF SELP NOS3 IL6 ICAM1
5
Show member pathways
12.92 VEGFA TNF IL6 ICAM1 HIF1A CCL2
6
Show member pathways
12.65 VEGFA VCAM1 NOS3 ICAM1 CCL2
7
Show member pathways
12.4 VEGFA VCAM1 NOS3 ICAM1 CCL2
8
Show member pathways
12.31 TNF IL6 CCL2 APOB
9
Show member pathways
12.24 TNF IL6 EDN1 ACE
10
Show member pathways
12.2 TNF IL6 ICAM1 CRP CCL2 APOE
11 12.17 VEGFA TNF IL6 HIF1A
12 12.03 TNF SELP IL6 ICAM1 CCL2
13 11.97 VEGFA NOS3 IL6 HIF1A EDN1
14 11.94 VEGFA VCAM1 TNF NOS3 ICAM1 EDN1
15 11.89 VCAM1 TNF IL6 ICAM1 EDN1 CCL2
16 11.88 VEGFA TNF IL6 ICAM1 CCL2
17 11.82 VWF NOS3 HIF1A F3 CCL2
18 11.76 VEGFA VCAM1 TNF IL6 ICAM1 HIF1A
19 11.71 VCAM1 TNF IL6 ICAM1
20 11.68 TNF IL6 EDN1 CCL2
21 11.66 VEGFA HIF1A EDN1
22
Show member pathways
11.65 VEGFA VCAM1 TNF IL6 ICAM1
23 11.61 VEGFA NOS3 HIF1A EDN1
24 11.56 TNF IL6 ICAM1 CCL2
25 11.54 VEGFA IL6 HIF1A
26 11.48 TNF IL6 APOE
27 11.48 VCAM1 NOS3 ICAM1
28 11.48 TNF SELP IL6 ICAM1 APOB
29 11.42 VCAM1 TNF IL6 ICAM1
30 11.38 VEGFA HIF1A EDN1
31 11.34 NOS3 IL6 CCL2
32 11.3 CCL2 APOE ACE
33 11.28 VEGFA VCAM1 TNF NOS3 IL6 ICAM1
34
Show member pathways
11.27 VEGFA HIF1A EDN1 CRP
35 11.16 VEGFA NOS3 HIF1A
36 11.13 VCAM1 TNF SELP IL6 ICAM1 CCL2
37 11.05 TNF IL6 CRP
38 10.94 VCAM1 TNF ICAM1 CCL2
39 10.63 VEGFA HIF1A

GO Terms for Peripheral Artery Disease

Cellular components related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 VWF VEGFA TNF PCSK9 IL6 F3
2 external side of plasma membrane GO:0009897 9.73 VCAM1 TNF SELP P2RY12 ICAM1 ACE
3 endoplasmic reticulum lumen GO:0005788 9.72 PCSK9 IL6 CST3 APOE APOB
4 cell surface GO:0009986 9.7 VEGFA VCAM1 TNF PCSK9 P2RY12 ICAM1
5 extracellular space GO:0005615 9.53 VWF VEGFA VCAM1 TNF SELP PCSK9
6 Weibel-Palade body GO:0033093 9.4 VWF EDN1
7 intermediate-density lipoprotein particle GO:0034363 9.37 APOE APOB

Biological processes related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.08 TNF SELP IL6 CRP CCL2
2 leukocyte migration GO:0050900 10 TNF SELP ICAM1 APOB
3 positive regulation of protein kinase B signaling GO:0051897 9.98 VEGFA TNF P2RY12 F3
4 cellular response to lipopolysaccharide GO:0071222 9.96 TNF IL6 ICAM1 CCL2
5 cellular protein metabolic process GO:0044267 9.93 PCSK9 IL6 CST3 APOE APOB
6 positive regulation of angiogenesis GO:0045766 9.92 VEGFA NOS3 HIF1A F3
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 VEGFA TNF ICAM1 CCL2 APOE
8 post-translational protein modification GO:0043687 9.91 PCSK9 IL6 HIF1A CST3 APOE APOB
9 cellular response to hypoxia GO:0071456 9.9 VEGFA ICAM1 HIF1A EDN1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 VEGFA TNF IL6
11 positive regulation of endothelial cell proliferation GO:0001938 9.88 VEGFA HIF1A F3
12 cellular response to organic cyclic compound GO:0071407 9.88 TNF P2RY12 CCL2
13 regulation of blood pressure GO:0008217 9.87 NOS3 EDN1 ACE
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF IL6 EDN1
15 positive regulation of MAP kinase activity GO:0043406 9.86 VEGFA TNF EDN1
16 positive regulation of interleukin-8 production GO:0032757 9.86 TNF IL6 F3
17 humoral immune response GO:0006959 9.86 TNF IL6 CCL2
18 response to hypoxia GO:0001666 9.85 VEGFA VCAM1 ICAM1 HIF1A EDN1
19 hemostasis GO:0007599 9.84 VWF P2RY12 F3
20 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 VEGFA NOS3 HIF1A
21 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.83 VCAM1 SELP ICAM1
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF ICAM1 EDN1
23 cellular response to interleukin-1 GO:0071347 9.8 ICAM1 HIF1A EDN1 CCL2
24 cellular response to tumor necrosis factor GO:0071356 9.8 VCAM1 ICAM1 EDN1 CCL2 APOB
25 protein kinase B signaling GO:0043491 9.79 TNF P2RY12 CCL2
26 positive regulation of chemokine production GO:0032722 9.78 TNF IL6 HIF1A
27 leukocyte cell-cell adhesion GO:0007159 9.76 VCAM1 SELP ICAM1
28 artery morphogenesis GO:0048844 9.74 VEGFA APOE APOB
29 positive regulation of nitric-oxide synthase activity GO:0051000 9.73 TNF HIF1A APOE
30 response to lipopolysaccharide GO:0032496 9.73 VCAM1 SELP NOS3 ICAM1 EDN1 APOB
31 lipoprotein metabolic process GO:0042157 9.72 PCSK9 APOE APOB
32 neutrophil mediated immunity GO:0002446 9.71 IL6 ACE
33 chylomicron remodeling GO:0034371 9.71 APOE APOB
34 negative regulation of platelet activation GO:0010544 9.7 NOS3 APOE
35 negative regulation of gene expression GO:0010629 9.7 VEGFA TNF HIF1A EDN1 CDKN2B-AS1 APOE
36 chylomicron remnant clearance GO:0034382 9.69 APOE APOB
37 leukocyte tethering or rolling GO:0050901 9.69 VCAM1 TNF SELP
38 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.67 VEGFA HIF1A
39 very-low-density lipoprotein particle clearance GO:0034447 9.67 APOE APOB
40 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.67 NOS3 EDN1
41 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.65 VEGFA ACE
42 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 TNF IL6 ICAM1
43 lipoprotein catabolic process GO:0042159 9.64 APOE APOB
44 lipoprotein biosynthetic process GO:0042158 9.64 APOE APOB
45 negative regulation of cellular protein metabolic process GO:0032269 9.63 EDN1 APOE
46 membrane to membrane docking GO:0022614 9.63 VCAM1 ICAM1
47 positive regulation of gene expression GO:0010628 9.61 VEGFA TNF NOS3 IL6 HIF1A F3
48 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.59 PCSK9 APOE
49 positive regulation of chemokine-mediated signaling pathway GO:0070101 9.58 HIF1A EDN1
50 negative regulation of lipid storage GO:0010888 9.54 TNF IL6 CRP

Molecular functions related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.62 VEGFA SELP APOE APOB
2 protease binding GO:0002020 9.46 VWF TNF F3 CST3
3 cytokine activity GO:0005125 9.35 VEGFA TNF IL6 EDN1 CCL2
4 very-low-density lipoprotein particle receptor binding GO:0070326 9.26 PCSK9 APOE
5 low-density lipoprotein particle receptor binding GO:0050750 8.92 PCSK9 CRP APOE APOB

Sources for Peripheral Artery Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....